ReviewClinical infectious diseases : an official publication of the Infectious Diseases Society of America2026
Why Are Gonorrhea Case Rates Declining in the United States? A Research Agenda.
Review in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
After nearly a decade of rising gonorrhea rates, the US Centers for Disease Control and Prevention (CDC) reported a decline in infection rates for 2 years in a row in 2022 and 2023, especially among young adults. While this warrants cautious optimism that control measures have been successful, the reasons for the decline are unknown. We do not know what lessons can be learned about the 4CMenB vaccine with partial protection against gonorrhea, doxycycline postexposure prophylaxis (doxy-PEP), asymptomatic screening, sexual behavior, or other possible drivers. Here, we enumerate potential drivers of the decline in gonorrhea, the evidence that argues for or against each one, and the data needed to clarify their roles. We hope to encourage those with suitable data to perform the analyses we outline, for surveillance systems to provide more detailed data where possible, and for existing and new surveillance and research studies to collect additional data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.